Obesity and diabetic hyperglycemia were associated with serum alanine aminotransferase activity in patients with hepatitis B infection

Metabolism: Clinical and Experimental

Volumn 59, Issue 4, 2010, Pages 486-491

  Wang, Ya Yu ^a,b   Lin, Shih Yi ^a,c   Sheu, Wayne Huey Herng ^a   Liu, Pi Hwa ^a   Tung, Kwong Chung ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HUMAN; HYPERGLYCEMIA; LIVER DYSFUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; AGED; ALANINE TRANSAMINASE; BODY MASS INDEX; DIABETES MELLITUS; FEMALE; HEPATITIS B; HUMANS; HYPERGLYCEMIA; LIVER; MALE; MIDDLE AGED; OBESITY;

EID: 77949428988     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.07.038     Document Type: Article

References (48)

1. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatitic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
2. Waneless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
3. Jimba S., Nakagami T., Takahashi M., Wakamatsu T., Hirota Y., Iwamoto Y., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose intolerance metabolism in Japanese adults. Diabet Med 22 (2005) 1141-1145
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
5. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
6. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
7. Parekh S., and Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132 (2007) 2191-2207
8. Poonawala A., Nair S.P., and Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 (2000) 689-692
9. Angulo P., keach J.C., Batts K.P., and Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
10. Samanic C., Gridley G., Chow W.H., Lubin J., Hoover R.N., and Fraumeni Jr. J.F. Obesity and cancer among white and black United States veterans. Cancer Causes Control 15 (2004) 35-43
11. El-Serag H.B., Tran T., and Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004) 460-468
12. Asselah T., Rubbia-Brandt L., MArcellin P., and Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 55 (2006) 123-130
13. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
14. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
15. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 109 (2000) 588-590
16. Clark J.M., brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
17. Erbey J.R., Silberman C., and Lydick E. The prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 124 (2000) 71-79
18. Ioannou G.N., Weiss N.S., Boyko E.J., Kahn S.E., and Lee S.P. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128 (2005) 627-635
19. WHO Expert Panel. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004) 157-163
20. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
21. Becker U., Deis A., Sorensen T.I., Grønbaek M., Borch-Johnsen K., Müller C.F., et al. Prediction of risk of liver disease by alcohol intake, sex, and age. A prospective population study. Hepatology 23 (1996) 1023-1025
22. Wang C.S., Wang S.T., Chang T.T., Yao W.J., and Chou P. Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. Arch Intern Med 162 (2002) 811-815
23. Kew M.C. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355 (2000) 591-592
24. Thomopoulos K.C., Arvaniti V., Tsamantas A.C., Dimitropoulou D., Gogos C.A., Siagris D., et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 18 (2006) 233-237
25. Altlparmak E., Koklu S., Yalinkilic M., Yuksel O., Cicek B., Kayacetin E., et al. Viral and host causes of fatty liver in chronic hepatitis. World J Gastroenterol 11 (2005) 3056-3059
26. Bondini S., Kallman J., Wheeler A., Prakash S., Gramlich T., Jondle D.M., et al. Impact of nonalcoholic fatty liver disease on chronic hepatitis B. Liver Int 27 (2007) 607-611
27. Tsochatzis E., Papatheodoridis G.V., Manesis E.K., Chrysanthos N., Kafiri G., and Archmandritis A.J. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis 39 (2007) 936-942
28. Cindoruk M., Karakan T., and Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gasteroenterol 41 (2007) 513-517
29. Tsochatzis E., Papatheodoridis G.V., Manesis E.K., Kafiri G., Tiniakos D.G., and Archmandritis A.J. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 27 (2008) 80-89
30. Chen C.L., Yang H.I., Yang W.S., Liu C.J., Chen P.J., You S.L., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135 (2008) 111-121
31. Yu M.W., Shih W.L., Lin C.L., Liu C.J., Jian J.W., Tsai K.S., et al. Body mass index and progression of hepatitis B: a population-based cohort in men. J Clin Oncol 26 (2008) 5576-5582
32. Wong G.L.H., Wong V.W.S., Choi P.C.L., Chan A.W.H., Chim A.M.L., Yiu K.K.L., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58 (2009) 111-117
33. Yamada J., Tomiyama H., Yambe M., Koji Y., Motobe K., Shiina K., et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 189 (2006) 198-205
34. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., and Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328 (2004) 983-986
35. Yuen M.F., Yuan H.J., Wong D.K., Yuen J.C., Wong W.M., Chan A.O., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
36. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B DNA level. JAMA 295 (2006) 65-73
37. Chu C.M., Lin D.Y., and Liaw Y.F. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes (Lond) 31 (2007) 871-875
38. Kim K.H., Shin H.J., Kim K., Choi H.M., Rhee S.H., Moon H.B., et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 132 (2007) 1955-1967
39. Huo T.I., Wu J.C., Lee P.C., Tsay S.H., Chang F.Y., and Lee S.D. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol 30 (2000) 250-254
40. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 (2001) 738-744
41. Nishida T., Tsuji S., Tsujii M., Arimitsu S., Haruna Y., Imano E., et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 101 (2006) 70-75
42. Gordon A., McLean C.A., Pedersen J.S., Bailey M.J., and Roberts S.K. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 43 (2005) 38-44
43. Papatheodoridis G.V., Chrysanthos N., Savvas S., Sevastianos V., Kafiri G., Petraki K., et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 13 (2006) 303-310
44. Wang Y.Y., Lin S.Y., Liu P.H., Cheung B.M., and Lai W.A. Association between hematological parameters and metabolic syndrome components in a Chinese population. J Diabetes Complications 18 (2004) 322-327
45. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
46. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27 (1998) 1213-1219
47. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53 (2004) 413-419
48. Hickman I.J., Clouston A.D., Macdonald G.A., Purdie D.M., Prins J.B., Ash S., et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51 (2002) 89-94